GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zhejiang Yatai Pharmaceutical Co 002370.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

4.58

-0.43%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥323.1m

FY2016FY2025

Net income

CN¥96.3m

FY2016FY2025

Free cash flow

CN¥23.8m

FY2016FY2025

Shareholders' equity

CN¥1.12bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥323.1mCN¥405.2mCN¥420.6mCN¥373.4mCN¥315.1mCN¥514.9mCN¥708.0mCN¥1.31bnCN¥1.08bnCN¥862.9m
Gross profitCN¥107.0mCN¥120.8mCN¥132.1mCN¥126.2mCN¥104.9mCN¥253.2mCN¥224.2mCN¥575.2mCN¥482.5mCN¥339.8m
Research and developmentCN¥15.5mCN¥14.6mCN¥21.8mCN¥26.1mCN¥28.6mCN¥37.3mCN¥69.6mCN¥57.2mCN¥43.6mCN¥27.0m
Operating income−CN¥12.2mCN¥28.2m−CN¥63.5m−CN¥116.6m−CN¥199.3mCN¥51.1m−CN¥1.92bnCN¥241.4mCN¥237.2mCN¥135.4m
Net incomeCN¥96.3mCN¥34.2m−CN¥11.9m−CN¥132.7m−CN¥228.3mCN¥27.3m−CN¥1.92bnCN¥207.8mCN¥202.2mCN¥125.3m
Diluted earnings per share0.130.04-0.02-0.26-0.420.05101.050.400.390.22

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥1.28bnCN¥1.40bnCN¥1.43bnCN¥1.52bnCN¥1.61bnCN¥1.96bnCN¥2.27bnCN¥3.54bnCN¥2.85bnCN¥2.43bn
Cash and short-term investments—CN¥743.9mCN¥720.5mCN¥757.6mCN¥821.1mCN¥902.9mCN¥1.18bnCN¥534.5mCN¥766.9mCN¥813.8m
Total liabilitiesCN¥159.4mCN¥429.6mCN¥848.5mCN¥1.22bnCN¥1.18bnCN¥1.30bnCN¥1.64bnCN¥1.16bnCN¥569.6mCN¥265.7m
Debt—CN¥30.1mCN¥689.5mCN¥951.8mCN¥974.4mCN¥1.01bnCN¥1.05bnCN¥263.8mCN¥40.0m—
Shareholders' equityCN¥1.12bnCN¥972.2mCN¥580.9mCN¥301.2mCN¥433.0mCN¥660.4mCN¥633.1mCN¥2.36bnCN¥2.27bnCN¥2.16bn
Shares outstanding718m886m731m514m538m578m—519m515m568m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥28.9mCN¥24.4mCN¥14.7mCN¥12.0m−CN¥3.8mCN¥17.8m−CN¥55.7mCN¥37.0mCN¥127.6m−CN¥38.0m
Capital spending−CN¥5.1m−CN¥9.9m−CN¥7.5m−CN¥21.1m−CN¥15.8m−CN¥39.1m−CN¥294.8m−CN¥630.9m−CN¥282.7m−CN¥75.9m
Free cash flowCN¥23.8mCN¥14.4mCN¥7.2m−CN¥9.1m−CN¥19.6m−CN¥21.3m−CN¥350.6m−CN¥593.9m−CN¥155.1m−CN¥114.0m
Dividends paid−CN¥37.4m−CN¥11.9m−CN¥16.5m−CN¥13.9m−CN¥13.3m−CN¥15.0m−CN¥44.4m−CN¥61.4m−CN¥28.2m−CN¥45.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥97.9mCN¥59.6mCN¥94.8mCN¥76.2mCN¥87.5mCN¥64.6mCN¥98.3mCN¥84.9m
Gross profitCN¥32.8mCN¥21.2mCN¥36.1mCN¥27.8mCN¥22.9mCN¥20.2mCN¥25.3mCN¥26.6m
Operating incomeCN¥7.8m−CN¥468,500CN¥7.7m−CN¥9.1mCN¥114.4m−CN¥8.0mCN¥31.4m−CN¥8.4m
Net incomeCN¥2.2m−CN¥2.6m−CN¥887,185−CN¥8.0mCN¥113.0m−CN¥7.8mCN¥37.7m−CN¥8.9m
Diluted earnings per share0.00-0.00-0.00-0.010.16-0.010.04-0.01
Cash from operations———−CN¥6.0mCN¥16.0mCN¥11.0m——
Capital spending−CN¥5.0m−CN¥1.0m—−CN¥2.0m−CN¥1.0m—−CN¥2.0m−CN¥1.0m
Free cash flow———−CN¥8.0mCN¥15.0m———
Total assetsCN¥1.19bnCN¥1.23bnCN¥1.28bnCN¥1.21bnCN¥1.24bnCN¥1.44bnCN¥1.40bnCN¥1.36bn
Cash and short-term investments———CN¥617.9mCN¥625.2mCN¥776.8mCN¥743.9mCN¥689.1m
Debt———CN¥15.3mCN¥33.9mCN¥30.0mCN¥30.1mCN¥606.6m
Shareholders' equityCN¥1.12bnCN¥1.12bnCN¥1.12bnCN¥1.12bnCN¥1.13bnCN¥997.9mCN¥972.2mCN¥625.4m

Financial ratios

Data as of 16 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin11.6%13.7%8.5%17.5%19.2%15.0%
Operating margin3.5%5.1%-2.6%-0.6%-12.5%-15.1%
Net margin1.1%1.6%-3.3%-5.5%-14.8%-14.8%
Return on equity8.0%14.2%-32.4%-164.5%492.1%-204.7%
Return on assets0.9%1.2%-2.6%-10.1%-13.7%-19.5%
Free cash flow yield3.9%0.2%1.0%17.6%-2.8%10.1%
Revenue growth-3.7%0.7%-63.6%-15.2%-40.4%-22.1%
Earnings growth-38.1%-149.8%-78.2%-68.3%-40.5%227.4%
Current ratio0.98x0.97x0.93x0.90x0.71x0.75x
Debt to equity2.13x0.56x2.69x0.14x-3.15x1.88x
Equity ratio10.9%8.6%7.9%6.1%-2.8%9.5%
Interest coverage6.27x10.34x-7.90x-0.23x-4.09x-10.03x
R&D as a share of sales0.9%1.2%1.5%3.1%3.9%2.6%
Buybacks as a share of market value0.4%0.2%-0.5%-0.1%0.2%-0.2%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-4.7%-8.9%-3.5%
Operating income-52.8%——
Net income—28.7%5.7%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin31.3%31.9%35.9%39.2%
Operating margin2.2%-10.8%-13.3%-23.0%
Net margin17.9%-0.9%-9.1%-22.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings54.578.9-264.2-19.0-10.679.50.141.536.666.4
Price to sales16.36.77.56.87.74.2-0.26.66.89.6

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 10 Jun 2019.

FY2019FY2018FY2017FY2016FY2015FY2014FY2012FY2011
Paid in the year0.050.100.050.050.050.010.040.044
  • 2-for-1 split · 20 Sept 2017
  • 17-for-10 split · 6 Jul 2011

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.